ArticleFrontiers in immunology2020
Tolerogenic Dendritic Cells Reduce Cardiac Inflammation and Fibrosis in Chronic Chagas Disease.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation.Infectious disease reports · 2026Review
- Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis.Regenerative therapy · 2026Review
- Integrating mechanical cues inFrontiers in immunology · 2026Review
- Gene- and cell-based therapy in cardiovascular diseases.Journal of cardiovascular pharmacology · 2025Article
- Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.European journal of heart failure · 2024Review
- Cardiac fibrogenesis: an immuno-metabolic perspective.Frontiers in physiology · 2024Review
- Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets.Frontiers in immunology · 2024Review
- Identification of key immune-related genes in dilated cardiomyopathy using bioinformatics analysis.Scientific reports · 2023Article
- Development of Adaptive Immunity and Its Role in Lung Remodeling.Advances in experimental medicine and biology · 2023Article
- High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells.Frontiers in medicine · 2023Article
- Immunomodulatory proteins from hookworms reduce cardiac inflammation and modulate regulatory responses in a mouse model of chronicFrontiers in parasitology · 2023Article
- Targeting regulatory T cells for cardiovascular diseases.Frontiers in immunology · 2023Review
- The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.Life sciences · 2022Review
- In the Acute Phase ofFrontiers in immunology · 2022Article
- The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2022Review
- Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?Frontiers in cellular and infection microbiology · 2022Review
- Comprehensive analysis of miRNA-mRNA regulatory network and potential drugs in chronic chagasic cardiomyopathy across human and mouse.BMC medical genomics · 2021Article
- GWAS loci associated with Chagas cardiomyopathy influences DNA methylation levels.PLoS neglected tropical diseases · 2021Article
- Reestablishment of Redox Homeostasis in the Nociceptive Primary Afferent as a Mechanism of Antinociception Promoted by Mesenchymal Stem/Stromal Cells in Oxaliplatin-Induced Chronic Peripheral Neuropathy.Stem cells international · 2021Article
- Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy.Frontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Chagas disease cardiomyopathy (CCC) is the most frequent and severe form of this parasitic disease. CCC is caused by a progressive inflammation in the heart, resulting in alterations that can culminate in heart failure and death. The use of dendritic cells (DCs) appears as an option for the development of treatments due to their important role in regulating immune responses. Here, we investigated whether tolerogenic cells (tDCs) could interfere with the progression of CCC in an experimental model of Chagas disease. The tDCs were generated and characterized as CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.